These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 28652773)

  • 1. Long-term outcomes of neoadjuvant chemotherapy followed by concurrent chemoradiotherapy (CCRT) vs CCRT alone for nasopharyngeal carcinoma in the era of intensity-modulated radiation therapy using propensity score matching method.
    Chen X; Zhu X; Liang Z; Li L; Qu S; Chen K; Pan X
    Onco Targets Ther; 2017; 10():2909-2921. PubMed ID: 28652773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can neoadjuvant chemotherapy improve survival in stage T3-4N1 nasopharyngeal carcinoma? A propensity matched analysis.
    Wang L; Wu Z; Xie D; Lv S; Xia L; Su Y
    Radiat Oncol; 2020 Jul; 15(1):160. PubMed ID: 32615984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Individualized Concurrent Chemotherapy for Patients with Stage III-IVa Nasopharyngeal Carcinoma Receiving Neoadjuvant Chemotherapy Combined with Definitive Intensity-Modulated Radiotherapy.
    Ji P; Lu Q; Chen X; Chen Y; Peng X; Chen Z; Lin C; Lin S; Zong J
    Cancer Res Treat; 2023 Oct; 55(4):1113-1122. PubMed ID: 37170497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of Neoadjuvant Chemotherapy in the Treatment of Nasopharyngeal Carcinoma: A Multi-institutional Retrospective Study (KROG 11-06) Using Propensity Score Matching Analysis.
    Song JH; Wu HG; Keam BS; Hah JH; Ahn YC; Oh D; Noh JM; Park HJ; Lee CG; Keum KC; Cha J; Cho KH; Moon SH; Kim JY; Chung WK; Oh YT; Kim WT; Cho MJ; Kay CS; Kim YS
    Cancer Res Treat; 2016 Jul; 48(3):917-27. PubMed ID: 26727716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of sequential chemoradiotherapy in stage II and low-risk stage III-IV nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A propensity score-matched analysis.
    Xu C; Sun R; Tang LL; Chen L; Li WF; Mao YP; Zhou GQ; Guo R; Lin AH; Sun Y; Ma J; Hu WH
    Oral Oncol; 2018 Mar; 78():37-45. PubMed ID: 29496056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival of stage II nasopharyngeal carcinoma patients with or without concurrent chemotherapy: A propensity score matching study.
    Liu DH; Zhou XY; Pan YG; Chen S; Ye ZH; Chen GD
    Cancer Med; 2020 Feb; 9(4):1287-1297. PubMed ID: 31859464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
    Wei Z; Zhang Z; Luo J; Li N; Peng X
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1857-1864. PubMed ID: 31062162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in stage III-IVb nasopharyngeal carcinoma patients with Epstein-Barr virus DNA ≥4000 copies/ml: a matched study.
    Guo SS; Tang LQ; Chen QY; Zhang L; Liu LT; Guo L; Mo HY; Luo DH; Huang PY; Xiang YQ; Sun R; Chen MY; Wang L; Lv X; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ
    Oncotarget; 2016 May; 7(20):29739-48. PubMed ID: 27105538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
    Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ
    Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IMRT combined with concurrent chemotherapy plus adjuvant chemotherapy versus IMRT combined with concurrent chemotherapy alone in patients with nasopharyngeal carcinoma.
    Zhong Q; Zhu X; Li L; Qu S; Liang Z; Zeng F; Pan X
    Oncotarget; 2017 Jun; 8(24):39683-39694. PubMed ID: 28147309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Individualized concurrent chemotherapy by pretreatment plasma Epstein-Barr viral DNA in II-III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort.
    Sun XS; Chen WH; Liu SL; Liang YJ; Chen QY; Guo SS; Wen YF; Liu LT; Xie HJ; Tang QN; Li XY; Yan JJ; Mai HQ; Tang LQ
    Cancer Med; 2019 Aug; 8(9):4214-4225. PubMed ID: 31210417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ten-Year Outcomes Of Intensity-Modulated Radiotherapy (IMRT) Combine With Chemotherapy Versus IMRT Alone For Stage II Nasopharyngeal Carcinoma In The Real-World Study (RWD).
    Ding XC; Fan PP; Xie P; Fan BJ; Yang J; Jiang LY; Bai XB; Yu JM; Hu M
    Cancer Manag Res; 2019; 11():8893-8903. PubMed ID: 31632149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent chemoradiotherapy combined with nimotuzumab in stage III-IVa nasopharyngeal carcinoma: a retrospective analysis.
    Cai Z; Chen D; Qiu W; Liang C; Huang Y; Zhou J; Zhan Z; Xiang Y; Guo X; Lv X
    J Cancer Res Clin Oncol; 2023 Jun; 149(6):2327-2344. PubMed ID: 36289067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of concurrent chemotherapy on locoregionally advanced nasopharyngeal carcinoma treated with neoadjuvant chemotherapy plus intensity-modulated radiotherapy: A retrospective matched analysis.
    Wang F; Jiang C; Wang L; Yan F; Sun Q; Ye Z; Liu T; Fu Z; Jiang Y
    Sci Rep; 2020 Feb; 10(1):2489. PubMed ID: 32051492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiotherapy with neoadjuvant chemotherapy versus concurrent chemoradiotherapy for ascending-type nasopharyngeal carcinoma: a retrospective comparison of toxicity and prognosis.
    Yao JJ; Yu XL; Zhang F; Zhang WJ; Zhou GQ; Tang LL; Mao YP; Chen L; Ma J; Sun Y
    Chin J Cancer; 2017 Mar; 36(1):26. PubMed ID: 28264724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction Chemotherapy plus Concurrent Chemoradiotherapy vs Concurrent Chemoradiotherapy in Elderly Patients with Advanced Nasopharyngeal Carcinoma.
    Wang C; Tang X; Wang J; Song J; Xu Y
    Otolaryngol Head Neck Surg; 2017 Aug; 157(2):233-238. PubMed ID: 28418781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimize the cycle of neoadjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with intensity-modulated radiotherapy: A propensity score matching analysis.
    Peng H; Chen L; Li WF; Zhang Y; Liu LZ; Tian L; Lin AH; Sun Y; Ma J
    Oral Oncol; 2016 Nov; 62():78-84. PubMed ID: 27865375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of chemotherapy in addition to concurrent chemoradiotherapy in T3-4N0-1 nasopharyngeal carcinoma: a propensity score matching study.
    Wu LR; Yu HL; Jiang N; Jiang XS; Zong D; Wen J; Huang L; Xie P; Chen W; Wang TT; Gu DY; Yan PW; Yin L; He X
    Oncotarget; 2017 Sep; 8(44):76807-76815. PubMed ID: 29100350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent chemoradiotherapy versus radiotherapy alone for patients with locally advanced esophageal squamous cell carcinoma in the era of intensity modulated radiotherapy: a propensity score-matched analysis.
    Li C; Tan L; Liu X; Wang X; Zhou Z; Chen D; Feng Q; Liang J; Lv J; Wang X; Bi N; Deng L; Wang W; Zhang T; Ni W; Chang X; Han W; Gao L; Wang S; Xiao Z
    Thorac Cancer; 2021 Jun; 12(12):1831-1840. PubMed ID: 33949784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma.
    Setakornnukul J; Thephamongkhol K
    BMC Cancer; 2018 Mar; 18(1):329. PubMed ID: 29587665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.